• EyeGene filed a corrected 2026 H1 semi-annual report dated Sept. 29, adding disclosures on treasury shares.
• Treasury shares held totaled 6,908 common shares as of June 30, equal to 0.01% of issued shares.
• Shares were acquired in 2021 through fractional-share processing tied to a bonus issue.
• No board-approved short-term or medium-to-long-term plan exists for acquisition, disposal, or cancellation as of June 30.
• Board plans to finalize a specific cancellation plan in 2027 H1 under amended Korean Commercial Act transition rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyeGene Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929000520), on September 29, 2026, and is solely responsible for the information contained therein.